BACKGROUND: Elevated levels of N-telopeptide of type I collagen (NTX) are associated with skeletal-related events and death. However, it is unclear whether NTX is useful for monitoring therapeutic response in non-small cell lung cancer (NSCLC) patients with bone metastases. PATIENTS AND METHODS: Urinary NTX levels were assessed at baseline and after one cycle of chemotherapy in 30 NSCLC patients with bone metastases. NTX levels were categorized as normal (NTX <64 nmol/mmol creatinine) or high (NTX ≥64 nmol/mmol creatinine). RESULTS: In 30 patients, the median NTX level at 1 month was significantly lower than that at baseline (P = 0.0016). The NTX levels after treatment were significantly lower than those at baseline in 20 patients with partial response (n = 2) or stable disease (n = 18). However, no significant difference of the NTX levels was observed in 10 patients with progressive disease. Sixteen (53.3%) of 30 patients had high baseline NTX levels. Ten patients had normal NTX levels after one cycle of chemotherapy, whereas 6 patients also had high NTX levels after treatment. The 10 patients with normal NTX levels had significantly better prognosis than the 6 patients with high NTX levels. CONCLUSION: Urinary NTX levels at 1 month after chemotherapy may be useful for predicting therapeutic response in NSCLC patients with bone metastases. Normalization of elevated baseline NTX at 1 month after chemotherapy was associated with survival benefits.
BACKGROUND: Elevated levels of N-telopeptide of type I collagen (NTX) are associated with skeletal-related events and death. However, it is unclear whether NTX is useful for monitoring therapeutic response in non-small cell lung cancer (NSCLC) patients with bone metastases. PATIENTS AND METHODS: Urinary NTX levels were assessed at baseline and after one cycle of chemotherapy in 30 NSCLCpatients with bone metastases. NTX levels were categorized as normal (NTX <64 nmol/mmol creatinine) or high (NTX ≥64 nmol/mmol creatinine). RESULTS: In 30 patients, the median NTX level at 1 month was significantly lower than that at baseline (P = 0.0016). The NTX levels after treatment were significantly lower than those at baseline in 20 patients with partial response (n = 2) or stable disease (n = 18). However, no significant difference of the NTX levels was observed in 10 patients with progressive disease. Sixteen (53.3%) of 30 patients had high baseline NTX levels. Ten patients had normal NTX levels after one cycle of chemotherapy, whereas 6 patients also had high NTX levels after treatment. The 10 patients with normal NTX levels had significantly better prognosis than the 6 patients with high NTX levels. CONCLUSION: Urinary NTX levels at 1 month after chemotherapy may be useful for predicting therapeutic response in NSCLCpatients with bone metastases. Normalization of elevated baseline NTX at 1 month after chemotherapy was associated with survival benefits.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Luis Costa; Laurence M Demers; A Gouveia-Oliveira; J Schaller; Eduardo B Costa; Miguel C de Moura; Allan Lipton Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: Janet E Brown; Richard J Cook; Pierre Major; Allan Lipton; Fred Saad; Matthew Smith; Ker-Ai Lee; Ming Zheng; Yong-Jiang Hei; Robert E Coleman Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506
Authors: Allan Lipton; Richard Cook; Fred Saad; Pierre Major; Patrick Garnero; Evangelos Terpos; Janet E Brown; Robert E Coleman Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: Maria A Lopez-Olivo; Nimit A Shah; Greg Pratt; Jan M Risser; Elaine Symanski; Maria E Suarez-Almazor Journal: Support Care Cancer Date: 2012-09-07 Impact factor: 3.603